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ABSTRACT Maternal transport of immunoglobulin to the
newborn mammal is important for immune defense during the
first weeks of independent life. Receptors for the Fc portion of
IgG mediate the transfer of immunoglobulin from milk to the
bloodstream of newborn mice and rats, by passage through
intestinal epithelial cells. Neonatal Fc receptors (FcRn) isolated
from intestinal epithelial cells of suckling rats bear a striking
resemblance to class I histocompatibility molecules. The heavy
chain of FcRn has sequence similarity in three extracellular
domains to the corresponding domains of class I molecules, and
the light chain of both types of molecules is (12-microglobulin.
To facilitate biochemical characterization and crystallization of
FcRn, we have expressed a secreted form, as well as two
different lipid-linked forms solubilizable by phospholipase
treatment. The lipid-linked forms are heterodimers consisting
of .82-microglobulin and the extracellular portion of the heavy
chain and are anchored to the membrane by a phosphatidyl-
inositol linkage attached to either the heavy chain or P82-
microglobulin. Cells expressing either lipid-linked form bind
rat Fc, reproducing the known physiological pH dependence of
binding. Secreted FcRn has been purified in yields up to 40
mg/liter from cell supernatants. Circular dichroism spectra of
soluble FcRn appear similar to spectra of class I MHC mole-
cules, suggesting that the similarities in primary sequence
extend also to a similarity in secondary structure. Soluble FcRn
crystallizes in a form amenable to a structure determination by
x-ray diffraction methods, which will ultimately allow a de-
tailed comparison of the two types of molecules.
Newborn rats acquire humoral immunity through ingestion of
milk containing maternal IgG. Fc receptors on the intestinal
epithelial cells of the neonate (FcRn) bind IgG from milk at
acidic pH (6.0-6.5) and transport it to the basolateral mem-
brane at the serosal side of the cell, where the IgG dissociates
at a pH of 7.4. FcRn has been affinity-purified from rat
intestinal epithelial cell brush borders and shown to be a
heterodimer consisting of two polypeptide chains of relative
molecular masses 45,000-53,000 (p51) and 14,000 (p14) (1).
The light chain is P2-microglobulin (f32m), a soluble protein
also found complexed to the heavy chains of class I major
histocompatibility complex (MHC) molecules. The similarity
between FcRn and histocompatibility molecules also extends
to the p5i subunit, which consists of three extracellular
domains, all with sequence similarity to the corresponding
domains of class I MHC proteins, and an unrelated cytoplas-
mic domain (2, 3). Class I MHC molecules bind short
peptides derived from intracellular proteins, which are trans-
ported along with the MHC molecule to the cell surface, and
stable cell surface expression appears to depend upon peptide
binding (4-7). Crystallographic analyses of the peptide bind-
ing sites of three human class I MHC molecules have
revealed extra electron density presumably corresponding to
images of bound endogenous peptides (8-10). It would be of
interest to determine whether the structurally related FcRn
molecule is also transported to the cell surface with endog-
enous peptide(s) and whether FcRn requires a bound peptide
for structural stability.
Here we report the expression of two different lipid-linked
forms and one secreted form of FcRn in a glutamine syn-
thetase-based amplifiable expression system developed at
Celltech, Berkshire, U.K. (11). Both lipid-linked forms re-
produce the physiological pH dependence of Fc binding and
can be released as soluble molecules from the membrane with
phosphatidylinositol-specific phospholipase C (PI-PLC). Sol-
uble FcRn can be purified from cell supernatants by affinity
chromatography on a rat IgG column at pH 6.5, with elution
of the protein at pH 8.0. Crystals of soluble FcRn diffract to
2.9-A resolution.
MATERIALS AND METHODS
Reagents. Rat IgG, fluorescein-conjugated rat Fc, and
phycoerythrin-conjugated F(ab')2 fragments of anti-rabbit
IgG were from Jackson ImmunoResearch. Fluorescein-
conjugated goat anti-mouse was from Cappel Products. Goat
anti-rabbit IgG-peroxidase conjugate and purified rabbit anti-
human j32m IgG for Western blots were from Boehringer
Mannheim. CNBr-activated Sepharose was from Pharmacia.
Endoglycosidase F/N-glycosidase F was from Boehringer
Mannheim. Methionine sulfoximine (MSX), phospholipase
C, and lentil lectin-Sepharose 4B were from Sigma. Dulbec-
co's modified Eagle's medium (DMEM), a minimum essen-
tial medium (aMEM), and dialyzed fetal bovine serum were
from Irvine Scientific and GIBCO/BRL. Anti-pSi is a rabbit
polyclonal antiserum against the FcRn heavy chain (2).
2B10C11, a mouse monoclonal antibody against rat f32m, was
the gift of Lennart Logdberg (Sandoz Pharmaceutical).
Construction of Lipid-Linked and Soluble Forms of FcRn.
Molecular biological experiments were performed by standard
methods (12). The p51-DAF and f32m-DAF chimeras were
constructed by methods similar to those used for the expres-
sion of a lipid-linked form of the T-cell antigen receptor (13).
The chimeric proteins consisted of the phosphatidylinositol
(PI)-anchoring signal of decay-accelerating factor (DAF; res-
idues 311-347; ref. 14) fused C-terminal to amino acid 269 of
the FcRn heavy chain or to the final amino acid of P2m.
Briefly, a BamHI fragment containing the full-length FcRn (2)
or rat (32m cDNA (N.E.S., unpublished data) was inserted 5'
to the DNA segment encoding the DAF PI-anchoring signal
(14) cloned in pBluescript SK(-) (Stratagene). Oligonucle-
otide-directed in vitro deletional mutagenesis (15) generated an
Abbreviations: FcRn, neonatal Fc receptor(s); f32m, /32-microglob-
ulin; MHC, major histocompatibility complex; PI-PLC, phosphati-
dylinositol-specific phospholipase C; DAF, decay-accelerating fac-
tor; MSX, methionine sulfoximine.
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in-frame fusion between the FcRn heavy chain (p51-DAF) or(32m (132m-DAF) and the PI-anchoring signal. Truncated FcRn
heavy chain was created by inserting a stop codon after amino
acid 269 (p51-stop) (Fig. 1A).
The modified cDNAs were introduced as Xho I-Not I
fragments into the unique Xho I and Not I sites in the
polylinker of the expression vector pBJ5-GS, a derivative of
pBJ1-Neo (13, 16). pBJ5-GS employs the glutamine synthetase
gene as a selectable marker and means of gene amplification
in the presence of the drug MSX, a system developed by
Celltech (11). (The glutamine synthetase minigene was re-
moved from the expression vector pSVLGS1 obtained from
Celltech and was cloned into the unique Sal I site of pBJ5 to
create pBJ5-GS.) The p51-stop gene and the unmodified f32m
gene were also cloned into pBJ1, so that a Sal I fragment
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FIG. 1. (A) Schematic diagram showing the structures of the
normal FcRn heavy chain [p51 wild type (WT)] and rat ,62m (82m
WT), and positions where the lipid-attachment sequence from DAF
was fused (p51-DAF and .82m-DAF) or where a stop codon was
introduced (p51-stop). The mature FcRn heavy chain consists of
three extracellular domains (al, a2, and a3) with sequence similarity
to the corresponding domains of class I MHC molecules, and an
unrelated transmembrane (TM) and cytoplasmic (CYT) region (2).
The lipid attachment signal from DAF (14) (residues 311-347) was
fused following residue 269 of the FcRn heavy chain (p51-DAF) or
following the final amino acid (residue 99) of 82m (,82m-DAF).
Residues N-terminal of the solid vertical line are retained in the
chimeric fusion proteins (14). (B) Triple expression vector used to
transfect CHO cells and express the proteins. GS, glutamine syn-
thetase gene (11); SRa, promoter used to regulate transcription of
downstream cDNAs (16); Amp, ampicillin-resistance gene. Arrows
indicate orientation of cDNA relative to the GS minigene.
containing the desired gene as well as the SRa promoter and
the simian virus 40 polyadenylylation signal could be cloned
into pBJ5-GS containing the appropriate partner gene. Three
such vectors were created: pBJ5-GS/p51-DAF//32m, to ex-
press PI-linked FcRn heavy chain with soluble j2m; pBJ5-
GS/p51-stop/f2m-DAF, to express truncated (soluble) FcRn
heavy chain with PI-linked ,32m; and pBJ5-GS/p5l-stop/,32m,
to express secreted heterodimer (Fig. 1B).
Production of the Three FcRn Forms in CHO Cells. The
expression vectors were transfected into CHO cells by a
calcium phosphate procedure (Stratagene). Selection and
amplification of the glutamine synthetase gene were carried
out according to the protocol established by Celltech. Briefly,
a calcium phosphate/DNA precipitate containing 30 pug of
pure DNA, or no DNA as a mock control, was added to CHO
cells in 10 ml of fresh DMEM with serum. The next day, the
cells were washed three times with aMEM without serum
and then incubated in aMEM with 10% dialyzed fetal bovine
serum and 25 ,uM MSX. Clones were visible after 2 weeks and
were isolated and grown in 24-well plates in aMEM with l1o0
dialyzed fetal bovine serum and 25 AM MSX. The cloning
procedure was repeated, and clones transfected with the two
lipid-linked forms of FcRn were tested for expression of both
protein subunits by immunofluorescence with anti-pSi and
2B1OC11. Positive clones were put in six-well plates and
submitted to increasing MSX concentrations from 50 to 500
pM. Clones were also tested for their ability to differentially
bind rat Fc at pH 6.5 as follows: 106 cells in suspension were
incubated for 1 hr at room temperature in 500 ,ul ofphosphate-
buffered saline (pH 6.5 or pH 8.0) with fluorescein-
conjugated rat Fc (0.5 pM) and then washed twice. The cell
pellet was resuspended in 1 ml of buffer at the appropriate pH
and analyzed by flow cytometry (Ortho cell sorter). Super-
natants from CHO clones transfected with pBJ5-GS/p51-
stop/P2m were tested for secreted FcRn heterodimer by
Western blotting with anti-pSl and a rabbit anti-human f32m
antiserum (crossreactive with rat p2m).
Phospholipase C Treatment. Cleavage of lipid-linked pro-
teins was done as described (13), but using a stock of
phospholipase C containing PI-PLC (Sigma P6135; 1 mg/ml),
which was added to 107 cells at a 100-fold dilution. Cells were
incubated for 2 hr at 37°C.
Purification of Soluble FcRn by Affinity Chromatography
and Biochemical Analysis. Rat IgG (70 mg) was covalently
linked to 7 ml of CNBr-activated Sepharose (10 mg/ml)
according to the manufacturer's directions. The pH of 100-
500 ml of supernatant from a CHO clone secreting FcRn
heterodimer growing in 100 AM MSX was decreased to pH
6.5 and put on the column at a constant flow rate of 20 ml/hr
at 4°C, and the column was washed with 300 ml of 50 mM
sodium phosphate, pH 6.5/0.05% NaN3. Elution of FcRn
was initiated with 50 mM sodium phosphate, pH 8.0/0.05%
NaN3. Fractions of 2 ml were collected and their optical
density at 280 nm measured. Typically, 10 mg of FcRn
heterodimer [quantified by bicinchoninic acid (BCA) assay;
Pierce] was eluted in six fractions from 250 ml of supernatant
harvested from 108-109 cells. The protein was concentrated
by Centricon 10000 filters. Deglycosylation of 10 pg of
purified protein was done for 16 hr in 50 mM Hepes (pH 7.5)
at 37°C with 0.5 unit of endoglycosidase F/N-glycosidase F.
N-Terminal Sequencing. N-terminal sequencing was per-
formed on 20-40 ,g of purified soluble FcRn in a phosphate
buffer dried on a poly(vinylidene difluoride) membrane (17)
and inserted into an Applied Biosystems model 4778 se-
quencer reaction cartridge.
CD Spectra. A Jasko J-600 spectropolarimeter was used in
the wavelength range of 190 to 260 nm with a 0.1-mm cell.
Purified HLA-B40 (gift of Don Wiley and Anastasia Haykov,
Harvard University) and soluble FcRn heterodimer were
concentrated to 0.1-0.5 mg/ml in 20 mM sodium phosphate
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(pH 8.0). The percent helix, p-strand, and disordered structure
(random) was estimated by fitting the spectra to reference data
(18) with a nonrestrained least-squares algorithm (19).
Crystallization of Soluble FcRn. Crystals were grown by
vapor diffusion from protein solutions (20 mg/ml) in 10 mM
Pipes, pH 6.5/0.05% NaN3, in 2-,ul droplets with 24.0%o
(wt/vol) polyethylene glycol 3350, 2.0% (wt/vol) saturated
ammonium sulfate, and 100 mM Pipes (pH 6.5).
RESULTS
Expression ofTwo Lipid-Linked Forms ofFcRn. An expres-
sion vector (Fig. 1B) containing the hamster glutamine syn-
thetase gene (11) (for selection and amplification), the gene
encoding the extracellular portion of the FcRn heavy chain
fused in-frame to the cDNA from DAF encoding its lipid
attachment signal (14), and the rat r2m gene was transfected
into CHO cells. Stable lines were generated and the trans-
fected gene was amplified by selection with MSX. Cell
surface expression of FcRn heavy and light chains was
detected by immunostaining with anti-p5i and anti-rat f32m
antibodies and was reduced after treatment with PI-PLC (Fig.
2 B) and B2). CHO cells expressing lipid-linked FcRn het-
erodimers bound rat Fc, and the physiological pH depen-
dence of Fc binding was reproduced, in that binding was
observed at pH 6.5 but not at pH 8.0 (Fig. 2D2). Binding was
inhibited by addition of unlabeled rat IgG or rat Fc at 100
lug/ml, but not by the equivalent amount of an unrelated
protein (data not shown). Expression ofthe lipid-linked FcRn
heavy chain in the absence of rat f32m was at a level
comparable to the expression in the presence of rat 82m (data
not shown), but the binding of fluorescein-conjugated rat Fc
was diminished (Fig. 2D4).
The second lipid-linked form of FcRn was expressed by
transfecting a plasmid containing theDNA encoding theDAF
PI-attachment signal (14) fused to the rat r2m gene, together
with the gene encoding the FcRn heavy chain truncated with
an in-frame stop codon after amino acid 269 (p51-stop), and
the glutamine synthetase gene (Fig. 1B). Stable CHO lines
expressing this lipid-linked form of FcRn were generated by
selection with MSX and stained with the anti-pSi and anti-rat
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f32m antibodies. Staining was reduced after treatment with
PI-PLC (Fig. 2 Cl and C2). The FcRn/f82m-DAF het-
erodimers also showed the expected pH dependence of Fc
binding (Fig. 2D3). Expression levels of the two forms of
lipid-linked FcRn heterodimers appeared comparable (Fig. 2
B) and Cl).
Expression of Secreted FcRn. An expression vector (Fig.
1B) containing the glutamine synthetase gene, the truncated
FcRn heavy chain gene, and the rat P2m gene was transfected
into CHO cells. Media collected from individual clones were
assayed for secretion of FcRn heterodimers by Western
blotting aliquots of supernatants with antibodies specific for
the heavy and light chains. Positive clones were amplified
with increasing amounts of MSX. Medium (250 ml) from a
high-expressing clone growing in 100 ILM MSX was adjusted
to pH 6.5 and passed over a rat IgG affinity column. The
column was extensively washed, and FcRn heterodimers
were eluted by changing the pH to 8.0, yielding -10 mg of
purified protein. The high-expressing CHO clone was grown
in a Cell Pharm II hollow-fiber bioreactor device (Unisyn
Fibertec, San Diego) in the presence of 100 IiM MSX. The
yield of soluble FcRn was typically 7-10 mg per daily harvest.
Purified FcRn was analyzed by SDS/17.5% PAGE (Fig. 3).
Under either reducing or nonreducing conditions, two bands
were detected: a sharp band of apparent molecular mass 13
kDa, corresponding to ,82m, and a broad diffuse band at -43
kDa, corresponding to the truncated FcRn heavy chain.
Treatment of purified FcRn with a mixture of endoglycosi-
dase F and N-glycosidase F had no effect on the apparent
molecular mass of h2m, but the majority of the heavy chain
shifted its position of migration to 30 kDa, in close agreement
with the predicted molecular mass of the unmodified trun-
cated heavy chain (30,274 daltons). Glycosidase-treated
FcRn did not bind to a lentil lectin column (data not shown),
also suggesting that all carbohydrate moieties were removed.
These data suggest that =13 kDa of the extra molecular mass
was due to N-linked glycosides, a figure that is not incon-
sistent with the utilization of all four potential N-linked
glycosylation sites in the FcRn heavy chain sequence (2).
Deglycosylated soluble FcRn retained its ability to bind to the
Fc affinity column (data not shown), suggesting that the
FIG. 2. Flow cytometric analyses of
CHO cells transfected with lipid-linked
forms of FcRn. (Al, Bl, and Cl) Staining
of cells by anti-pSi [secondary antibody
is a phycoerythrin-conjugated F(ab')2
fragment of anti-rabbit IgGI. (A2, B2, and
C2) Staining by 2B1OC11 (anti-rat P2m;
secondary antibody is fluorescein-la-
beled goat anti-mouse IgG). -*, Second-
ary antibody alone. -, Primary and sec-
ondary antibodies. ---, Both antibodies,
cells treated with phospholipase C. (Be-
cause the anti-p51 serum is cytotoxic for
the transfected cells, the difference in
staining after phospholipase C treatment
is difficult to detect and is shown only for
staining by 2B1OC11.) Cells were un-
transfected (Al and A2) or were trans-
fected with p5l-DAF/,32m (BE and B2) or
p51-stop/B2m-DAF (Cl and C2). (Dl-
D4) Binding of fluorescein-labeled rat Fc
to transfected cell lines at pH 8 (-)
versus pH 6.5 (-). Cells were untrans-
fected (Dl) or were transfected with p51-
DAF/132m (D2), p51-stop/P2m-DAF(D3), or p51-DAF (D4).
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FIG. 3. SDS/17.5% PAGE comparison ofpurified secreted FcRn
before (lanes a and c) and after (lanes b and d) treatment with
endoglycosidase F/N-glycosidase F. Samples were run under nonre-
ducing (lanes a and b) or reducing (lanes c and d) conditions.
carbohydrate moieties were not involved in the interaction
between FcRn and Fc.
Purified soluble FcRn was subjected to N-terminal se-
quence analysis to verify the origin of the (32m species
associated with the FcRn heavy chain and to look for possible
peptides associated with the FcRn heavy chain. Since the
sequence of hamster 82m was previously unknown, a cDNA
library was constructed from CHO cell RNA, and a hamster
f32m clone was isolated and sequenced (L.N.G., unpublished
data; EMBL data library, accession no. X57112). The first 16
residues of bovine (20) and rat (21) (32m differ at amino acid
residues 3, 4, and 6 (ofthe mature protein), and the sequences
of hamster and rat ,32m differ at residues 3, 4, 7, and 11. Two
N-terminal sequences in equimolar amounts were identified
in the FcRn sample: the sequence AEPRLPLMYH-
LAAVSD, corresponding to the first 16 amino acids of the
mature FcRn heavy chain (3), and the sequence IQKTP-
QIQVYSRHPPE, corresponding to the sequence of the first
16 residues of mature rat 32m (21). No evidence of sequences
corresponding to bound peptides was seen.
CD Spectral Comparison of Soluble FcRn and MHC Class I
Proteins. Analysis of CD spectra of HLA-B40 and soluble
FcRn (Fig. 4) by a nonrestrained least squares fitting proce-
dure indicated a dominant B-strand component with a minor
helical contribution, similar to that reported previously (22,
23) for HLA-B7 and HLA-A2, although lower amounts of
p-structure were predicted for other class I MHC molecules
from CD spectral analyses (23, 24). The percent helix esti-
mated from our analysis of the spectrum of HLA-B40 agrees
well with the amount found in class I MHC crystal structures
(8-10) (-20% helix), but our CD analysis predicts a higher
content of 8-structure than is found in the crystal structures
(8-10) (-42% f-structure). We have noted a discrepancy in
calculated P-structure by using another method of analysis
(28), but both methods suggest that FcRn and HLA-B40 have
similar percentages of secondary structural elements.
Crystals of Soluble FcRn. Soluble FcRn protein forms
crystals of approximate dimensions 0.3 mm x 0.1 mm x 0.1
mm in space group C2221 (Fig. 5). The unit cell dimensions
are a = 126.4 A, b = 191.7 A, and c = 149.6 A. The
asymmetric unit of the crystal is estimated to contain two to
four molecules based on average volume to mass ratios (Vm)
of protein crystals (25), representing solvent contents be-
tween 73% (if two molecules per asymmetric unit) to 32% (if
four molecules per asymmetric unit). The crystals diffract to
3.5-A resolution using nickel-filtered CuKa radiation from a
rotating-anode x-ray generator but suffer from radiation
damage such that data can be collected only to 4-A reso-
lution. The use of a synchrotron x-ray source (SSRL, Stan-
ford University) greatly improves the resolution limit, and a
complete native data set to 2.9-A resolution has been col-
lected. Single crystals ofa complex between FcRn and rat Fc
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FIG. 4. Far-UV CD spectra of FcRn (-, 0.24 mg/ml) and
HLA-B40 ( , 0.12 mg/ml) expressed as ellipticity per mean residue.
have also been obtained (A. H. Huber, L.N.G., and P.J.B.,
unpublished results).
DISCUSSION
As a first step in a biochemical and structural analysis to
address questions raised by the intriguing structural similar-
ity between FcRn and MHC class I molecules, we have
expressed large quantities of three different forms of soluble
FcRn. A strategy for secretion of a normally membrane-
bound heterodimeric glycoprotein by deletion of the trans-
membrane region through introduction of an in-phase trans-
lation stop codon has not always proved successful. There-
fore we initially constructed two different lipid-linked forms
of FcRn, which can be solubilized by treatment with PI-PLC.
The first form was anchored to the membrane by attaching
the lipid-anchoring signal from DAF (14) following amino
acid 269 of the FcRn heavy chain and was expressed together
with rat f32m in CHO cells, using a glutamine synthetase-
based amplifiable expression system (11). [Residue 269 is the
counterpart of the MHC class I residue 274, which is the last
residue of the class I a3 domain (2).] The second lipid-linked
form of FcRn consisted of the FcRn heavy chain truncated
after residue 269, which was expressed together with rat f32m
anchored to the membrane via a lipid-anchoring signal at-
tached to its C-terminal residue. With this form of FcRn, we
hoped to address the potential problem of the exchange of rat
f32m for bovine f32m in the medium or for hamster /32m inside
the CHO cells. Class I MHC molecules on the surface of
cultured cells associate with heterologous f82m from serum
FIG. 5. -Crystals of soluble FcRn.
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(26). It is thus conceivable that the structurally similar FcRn
might do the same, resulting in a heterogenous population of
molecules not amenable to crystallization. On cells express-
ing this second lipid-linked form of FcRn, we reasoned that
the only FcRn heterodimers released from the membrane
after PI-PLC treatment would be associated with rat 832m
rather than with bovine or hamster f2m. PI-PLC treatment of
cells expressing a truncated class I MHC heavy chain asso-
ciated with a PI-anchored form of 32m might also be a method
of producing a homogeneous population of soluble class I
MHC heterodimers.
Expression of the FcRn heavy chain and rat f32m was
detected at the cell surface of CHO clones expressing either
lipid-linked form of FcRn by flow cytometry, using an
anti-pSi antiserum (2) and a monoclonal antibody specific for
rat fi2m. Staining was diminished by treatment of cells with
PI-PLC (Fig. 2 B1, B2, and C2). In the case of the first
lipid-linked form of FcRn, it is possible that some of the cell
surface rat f32m detected is associated with hamster class I
MHC molecules, but by necessity, all of the truncated FcRn
heavy chain detectable at the cell surface in the second
lipid-linked form is paired with the rat f2m-DAF chimera.
Both lipid-linked forms of FcRn bind labeled rat Fc at pH 6.5,
but not at pH 8.0 (Fig. 2D1-4), reproducing the physiological
pH dependence of Fc binding, and confirming that the
presence of the PI anchor on either of the polypeptide chains
does not interfere with proper heterodimer formation or Fc
binding. Diminished binding of rat Fc to lipid-linked heavy
chains transfected in the absence of rat 132m (Fig. 2D4)
suggests that the FcRn molecule is not fully functional in the
absence of rat 182m, even when paired with a hamster or
bovine P2m light chain.
Because the truncated p51 FcRn heavy chain was capable
ofbeing transported to the surface ofthe cell, and because little
or no exchange of rat /32m with bovine or hamster P32m
occurred, we next attempted to make a secreted form of FcRn.
The gene encoding the truncated FcRn heavy chain was
transfected together with the rat f32m gene, again using the
Celltech glutamine synthetase-based amplifiable expression
system. With this expression system, a high level of expres-
sion can be obtained after an initial selection, and gene
amplification is rapidly achieved. Clones secreting soluble
FcRn heterodimer were evaluated for relative expression
levels by analysis of supernatant samples on Western blots,
and a high-expressing clone secreting FcRn at 40 mg/liter was
selected at 100 ILM MSX. FcRn was purified on a rat IgG
affinity column by passing supernatants over the column at pH
6.5 and eluting protein at pH 8.0. This purification scheme is
gentle, taking advantage of the physiological pH dependence
of Fc binding, thereby avoiding the harsh elution conditions
necessary for elution of immunoaffinity columns (27).
SDS/PAGE analysis of purified FcRn showed two bands
corresponding to truncated heavy chain and f2m. No evi-
dence of covalent dimerization of the FcRn heavy chain
mediated by a disulfide bond (1) was seen by comparison of
the mobility under reducing and nonreducing conditions, and
purified FcRn was eluted from a gel filtration column at the
position expected for a complex of a single heavy and light
chain (data not shown). Microsequencing of FcRn het-
erodimer revealed the expected N-terminal residues of the
heavy chain and rat f32m in equimolar amounts, suggesting
that f82m exchange either was minimal or did not occur.
Because the structurally related class I MHC molecules are
transported to the cell surface with peptides derived from
intracellular proteins and appear to depend upon the presence
of bound peptide for structural stability (4-7), we were
interested to see whether FcRn heterodimers showed evi-
dence ofbound peptide. No other sequences were detectable,
suggesting that the FcRn heterodimer was not complexed
with a unique peptide. A mixture of peptides would probably
not have been detected and cannot be ruled out as a possi-
bility.
Samples of soluble FcRn and the human class I MHC
molecule HLA-B40 were analyzed by CD spectroscopy (Fig.
4). Analysis of CD spectra of the class I molecule was
reasonably consistent with the known class I x-ray structures
(8-10) and with previously reported CD spectra (22, 23),
suggesting that the molecule is primarily composed of
(3-structure with a minor a-helical contribution. The CD
spectrum of soluble FcRn appears similar, which together
with the primary sequence similarity (2) further suggests that
the two types of molecules may adopt similar tertiary struc-
tures. X-ray structural analysis of single crystals of soluble
FcRn should ultimately allow the comparison of the two
related molecules at atomic resolution and facilitate greater
knowledge of the function of FcRn.
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